Skip to main content


Table 2 Synergy, antagonism, and additivity in LCC6 and LCC6Her2 cells treated with QLT0267 in combination with several clinically relevant agents

From: QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model

Chemotherapeutic agent Drug concentration range QLT0267: Drug ratio (nM)1 Result2
Cisplatin 0.15 to 20.0 μM 1, 2, 4: 1 Antagonistic at all ratios
Doxorubicin 0.0625 to 2.0 μM 10, 20, 40: 1 Antagonistic at all ratios
Paclitaxel 0.313 to 15.0 nM 1000, 4000:1 Antagonistic at all ratios
Vinorelbine 0.0625 to 4.0 nM 10,000, 20,000, 40,000: 1 Antagonistic at all ratios
Docetaxel 0.125 to 1.0 nM 50,000, 95,000: 1 Synergistic at all ratios
Trastuzumab 3.1 × 10-7 to 1 mg/ml 50,000: 1 mg/ml Variable
  1. 1 Drug ratios were chosen based on effective dose values of single agent treatment.
  2. 2 Synergy is defined as a combination that exhibits combination index values of less then one at high affect levels over a minimum of four drug concentrations.